Background: CUB-domain containing- protein 1 (CDCP1) is a transmembrane receptor involved in the progression of several cancers. Recent studies demonstrate that CDCP1 is a rational target for the development of innovative targeted therapies for cancer including theranostics agents and antibody-drug conjugates.
He Yaowu合作论文数4
Thomas Kryza合作论文数2CEPR INSERM U1100/EA 6305, Faculté de Médecine, 10 Blvd. Tonnellé, F-37032 Tours cedex, France. nathalie.vourch@med.univ-tours.fr.4
John D. Hooper合作论文数Magnusson Klemencic Associates, Inc4R. Giri合作论文数2M. Gala合作论文数2Veronika Schreiber合作论文数Faculty of Medicine, The University of Queensland2R. Gordon合作论文数2
Ailith Ewing合作论文数MRC Human Genet Unit, Univ Edinburgh2
Sumaira Hasnain合作论文数Mater Research Institute, Faculty of Medicine, The University of Queensland2
Graham Magor合作论文数Mater Research Institute, The University of Queensland;Mater Research Institute, The University of Queensland2
Jakob Begun合作论文数University of Virginia Health System, Universitatsklinikum Hamburg-Eppendorf2
Andrew C. Perkins合作论文数Department of Physiology, Monash University2G. Ratnayake合作论文数1
Kayden Kwah合作论文数1
Chris Pyke合作论文数1Madeline Gough合作论文数1S. Puttick合作论文数1T. Cuda合作论文数1Bergot Anne-Sophie合作论文数Princess Alexandra Hospital, The University of Queensland Diamantina Institute1
Timothy Florin合作论文数University of Queensland;Translational Research Institute1
Snell Cameron合作论文数1
